From GlobeNewswire:

RxSight, an ophthalmic medical device company, announced preliminary unaudited financial results for the fourth quarter and full-year 2023. Fourth quarter revenue is estimated to be $28.6 million, a 78% growth over the previous year. The 2023 fiscal year revenue is expected to be around $89.1 million, an 82% increase over the previous year. Looking ahead, RxSight forecasts a full-year 2024 revenue of $128.0 million to $135.0 million, reflecting 44% to 52% growth over 2023. The company expects to continue its growth in LAL procedures and LDD placements based on these results.



Read more: RxSight, Inc. Announces Preliminary Unaudited Fourth